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Abstract
Although treatment with interleukin-7 (IL-7) was shown to transiently expand the naı ¨ve and memory T-cell pools in patients
with chronic HIV-1 infection receiving antiretroviral therapy (ART), it is uncertain whether a full immunologic reconstitution
can be achieved. Moreover, the effects of IL-7 have never been evaluated during acute HIV-1 (or SIV) infection, a critical
phase of the disease in which the most dramatic depletion of CD4
+ T cells is believed to occur. In the present study,
recombinant, fully glycosylated simian IL-7 (50 mg/kg, s.c., once weekly for 7 weeks) was administered to 6 rhesus macaques
throughout the acute phase of infection with a pathogenic SIV strain (mac251); 6 animals were infected at the same time
and served as untreated controls. Treatment with IL-7 did not cause clinically detectable side effects and, despite the
absence of concomitant ART, did not induce significant increases in the levels of SIV replication except at the earliest time
point tested (day 4 post-infection). Strikingly, animals treated with IL-7 were protected from the dramatic decline of
circulating naı ¨ve and memory CD4
+ T cells that occurred in untreated animals. Treatment with IL-7 induced only transient T-
cell proliferation, but it was associated with sustained increase in the expression of the anti-apoptotic protein Bcl-2 on both
CD4
+ and CD8
+ T cells, persistent expansion of all circulating CD8
+ T-cell subsets, and development of earlier and stronger
SIV Tat-specific T-cell responses. However, the beneficial effects of IL-7 were not sustained after treatment interruption.
These data demonstrate that IL-7 administration is effective in protecting the CD4
+ T-cell pool during the acute phase of SIV
infection in macaques, providing a rationale for the clinical evaluation of this cytokine in patients with acute HIV-1 infection.
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Introduction
Although HIV-1 establishes a chronic active infection that
evolves toward clinical immunodeficiency over a span of several
years, accumulating evidence indicates that critical pathogenic
events take place during the acute phase of infection, leading to a
massive and seemingly irreversible depletion of CD4
+ T cells,
predominantly of the memory phenotype [1,2]. A large fraction of
the T-cell pool in the body is harbored in the gut-associated
lymphoid tissue (GALT) [3], which has been identified as a primary
anatomical site for CD4
+ T-cell depletion in both HIV-1-infected
patients [4–6] and SIV-infected nonhuman primates [1,2,7,8]; yet,
the loss of CD4
+ T cells within the early phase of infection appears
to be a systemic phenomenon that involves all secondary lymphoid
organs [1,9,10]. Taken together, these observations suggest that
interventions aimed at preventing or reducing the immunologic
damage caused by HIV-1 would be most effective if implemented
during the earliest stages of infection, before the pool of memory
CD4
+ T cells becomes irreversibly compromised.
In spite of extensive research over the past three decades, the
mechanism of CD4
+ T-cell depletion during the course of HIV-1
infection is still debated. Studies in SIV-infected macaques have
highlighted the role of direct cytopathic effects of the virus during
the course of acute primary infection [1,9,10]. However, indirect
mechanisms, including bystander apoptosis, may also be impor-
tant, as suggested by the increased levels of apoptosis detected in
blood and lymphoid organs of macaques acutely infected with
pathogenic SIV strains [2,11–15], as well as in ex vivo-cultured T
cells from individuals with acute HIV-1 infection [16–18]. Thus,
the use of anti-apoptotic agents during primary HIV-1 infection
may have beneficial effects for preserving the integrity of the CD4
+
T-cell pool. We previously demonstrated that interleukin-7 (IL-7),
a nonredundant cytokine that plays a critical role in the
development and homeostasis of the T-lymphoid compartment
PLoS Pathogens | www.plospathogens.org 1 April 2012 | Volume 8 | Issue 4 | e1002636of the immune system [19–21], effectively reduces the levels of
spontaneous apoptosis in both CD4
+ and CD8
+ T cells from HIV-
1-infected individuals [22]. In lymphopenic hosts, the levels of
endogenous IL-7 increase, causing transient proliferation of naı ¨ve
and central memory (CM) CD4
+ and CD8
+ T cells, which
eventually leads to the reconstitution of the physiological T-
lymphocyte pool [20–22]. Owing to these unique biological
properties, IL-7 is currently under clinical investigation as an
immune-reconstitution agent in various forms of natural and
iatrogenic immunodeficiencies, including those associated with
AIDS and cancer [23,24]. Pre-clinical studies in macaques
chronically infected with SIV [25–28], as well as clinical studies
in patients with HIV-1 infection or receiving treatment with
immunosuppressive antineoplastic drugs [29–32], have document-
ed beneficial effects of short-term courses of IL-7 therapy, resulting
in the proliferation and numerical expansion of naı ¨ve and CM
CD4
+ and CD8
+ T cells in peripheral blood and secondary
lymphoid organs. Whether adjuvant therapy with IL-7 may
effectively lead to the long-term reconstitution of the immunologic
function remains unclear. Moreover, IL-7 treatment has never
been evaluated in acute HIV-1/SIV infection, a phase in which it
may still be possible to avert the seemingly irreversible immuno-
logic damage caused by massive viral replication prior to the
appearance of virus-specific adaptive immune responses.
Inthepresentstudy,weadministeredfullyglycosylatedsimianIL-7
to rhesus macaques during the acute phase of infection with a
pathogenic SIV strain (mac251). The concomitant use of ART was
deliberately avoided in order to exclude its confounding effects on
pathogenesis since ART would have suppressed SIV replication,
thereby preventing the pathologic depletion of CD4
+ T-cells and
making it impossible to evaluate the CD4-protective effects of IL-7.
Another important goal of our study was to examine the effects of IL-
7 on SIV replication since IL-15, a related common-c-chain cytokine,
was recently shown to dramatically increase SIV replication and
accelerate disease progression when administered to acutely-infected
macaques [33]. Our results demonstrate that treatment with IL-7
during the acute phase of SIV infection is safe and effective in
preventing the decline of circulating naı ¨ve and memory CD4
+ Tc e l l s
without causing major increases in the levels of SIV replication.
Results
Safety and pharmacokinetics of glycosylated macaque IL-
7
None of the 6 rhesus macaques treated with IL-7 exhibited
adverse clinical side effects throughout the treatment period. After
the first IL-7 injection (day 27 relative to SIV infection), plasma
IL-7 levels peaked on day 25 to return to baseline on day 0
(Figure 1A). The two subsequent injections (day 0 and day 7)
induced higher peak levels of plasma IL-7 and a greater area
under the curve (AUC), resulting in markedly elevated trough
levels before each of the following injections. This pattern likely
reflects the initial distribution of the cytokine to a high-affinity
compartment that was saturated upon subsequent injections.
Increased plasma levels of IL-7, albeit considerably lower than in
IL-7-treated animals, were also observed in untreated animals
starting on day 28 post-infection in parallel with the most
pronounced reductions in circulating lymphocyte counts
(Figure 1A). No significant correlations were found between
plasma levels of IL-7 and various immunological parameters,
including circulating CD4
+ and CD8
+ T-cell counts and
expression of the specific chain of the IL-7 receptor (IL-7Ra or
CD127) (data not shown). In agreement with previous studies [25–
32], IL-7 treatment initially caused a significant downmodulation
Figure 1. IL-7 pharmacokinetics and CD127 expression in
circulating T cells in IL-7-treated and untreated animals. (A)
Plasma IL-7 concentrations in IL-7-treated and untreated macaques. IL-
7-treated animals received 7 weekly injections of 50 mg/kg of body
weight of a recombinant, fully glycosylated form of simian IL-7 (the grey
shaded area indicates the IL-7-treatment period). The asterisks denote
significant differences with baseline values (p,0.05 by paired Student’s
t test). (B) CD127 expression on total, naı ¨ve, memory and effector CD3
+
T cells from untreated (blue) and IL-7-treated (red) animals. Average
values of mean fluorescence intensity (MFI) 6 standard error of the
mean (SEM) from each group of macaques are shown. Blue and red
asterisks denote significant differences with baseline values (day 27) in
untreated and treated animals, respectively (* p,0.05, ** p,0.01, by
paired Student’s t test).
doi:10.1371/journal.ppat.1002636.g001
Author Summary
The development of highly effective cocktails of antiret-
roviral drugs has had a major impact on the survival and
quality of life of individuals with HIV-1 infection. Yet,
current protocols often fail to fully restore the immuno-
logic function, a limitation that has prompted the clinical
evaluation of immune-reconstitution agents, such as IL-7,
as adjuvant therapies. To date, however, IL-7 has been
tested exclusively in patients with chronic HIV-1 infection,
while it appears that the immune system is irreparably
damaged during acute primary infection, within the first
few weeks after encountering the virus. We used a
macaque model to show that treatment with IL-7 has
beneficial effects if implemented during the acute phase of
infection with SIV, the simian AIDS virus. Early administra-
tion of IL-7 was safe and effectively protected CD4
+ T cells,
the primary target cells for the virus, from the marked
decline that typically occurs during acute SIV infection.
Furthermore, IL-7 boosted the development of antiviral
immune responses. Thus, IL-7 might be an effective
adjuvant therapy in acute HIV-1 infection, which can
protect the pool of CD4
+ T cells before it is irreversibly
compromised by the action of the virus.
IL-7 Protects CD4
+ T Cells in Acute SIV Infection
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(Figure 1B).
IL-7 treatment during the acute phase of SIV infection
did not cause major increases in the levels of SIV
replication and proviral SIV DNA load
Comparison of the two groups of animals showed that treatment
with IL-7 did not induce significant increases in the levels of SIV
plasma viremia at any time during the acute phase of infection and
the follow-up period, including the peak of viral replication, the
viral set point and the AUC, with the only exception of the earliest
time point analyzed (day 4 post-infection; p=0.043 for the
comparison between the two groups of animals by Wilcoxon rank
sum test) (Figure 2A). However, there was a trend towards higher
levels of viremia in IL-7-treated animals, particularly on days 35
and 41 post-infection, even though the statistical p values
remained far below the threshold for significance (Table S1 in
Text S1). Likewise, the two groups of animals showed no
significant differences in the levels of SIV p27 antigenemia
(Figure 2B and Table S1 in Text S1) and proviral SIV DNA load
detected in blood mononuclear cells on days 14 and 77, in the
GALT (ileum) on days 14–16, and in axillary lymph nodes on days
25–27 post-infection (Figure 2C and Table S1 in Text S1). All the
animals developed SIV-specific IgG antibodies, which became
detectable between day 11 and day 21 of infection (data not
shown).
During the follow-up period, 4 animals (two untreated and two
IL-7-treated) developed early signs of progression to AIDS (rapid
progressors [RP]) and were euthanized for terminal disease within
5 months of infection. The RP course has been suggested to
represent a unique form of SIV disease, distinct from that of
conventional progressors (CP) and associated with an unusual
pathogenesis characterized by higher levels of SIV viremia,
massive SIV replication in mononuclear phagocytic cells rather
than in CD4
+ T cells (with consequent lack of depletion of CD4
+ T
cells), and severe SIV-related enteropathy in the absence of
opportunistic infections [34]. Additional data on RP animals are
presented in Supplementary Data and Figure S1 in Text S1. Since
the presence of RP animals could be a confounding factor in our
study, all the virological and immunological data were analyzed
both with the inclusion and after the exclusion of the 4 RP
animals. When the analysis of SIV plasma viremia and
antigenemia was restricted to CP animals, the statistical compar-
isons between IL-7-treated and untreated animals did not show
any significant changes from those obtained with the inclusion of
all the animals (Figure S2A in Text S1).
IL-7 treatment during the acute phase of SIV infection
prevented the decline of circulating naı ¨ve and memory
CD4
+ T cells
While all the animals in the untreated group experienced a
marked and sustained decline of circulating CD4
+ T lymphocytes
starting at the time of peak SIV replication (day 14 post-infection),
IL-7-treated animals showed no decline of CD4
+ T-cell counts
over the entire treatment period, with even a significant increase,
relative to baseline, on day 41 (Figure 3A). When the two groups of
animals were compared, IL-7-treated macaques had significantly
higher absolute numbers of peripheral CD4
+ T cells at several
time points, including day 14 post-infection (statistical data not
shown); similar results were obtained by comparison of the
changes in CD4
+ T-cell counts from baseline in IL-7-treated
versus untreated animals (Figure S3 in Text S1).
To better characterize the effects of IL-7 on CD4
+ T cells, the
naı ¨ve, memory and effector subpopulations were analyzed
separately. In the absence of IL-7 treatment, SIV infection caused
significant decreases in the absolute numbers of naı ¨ve and memory
CD4
+ T cells, compared to pre-infection levels, throughout the
acute phase of the infection (Figure 3A). In contrast, IL-7 caused
an initial increase in memory CD4
+ T cells (day 7) and
subsequently prevented the decline of both naı ¨ve and memory
CD4
+ T cells throughout the treatment period; effector CD4
+ T
cells were increased at several time points (Figure 3A). However,
the protective effects of IL-7 were not sustained after treatment
interruption with both naı ¨ve and memory CD4
+ T cells becoming
significantly decreased, compared to baseline values, on day 62
post-infection, 4 weeks after the last injection of IL-7 (Figure 3A).
When the absolute numbers of circulating naı ¨ve, memory and
effector CD4
+ T cells in the two groups of animals were compared,
significant differences were detected at several time points
(statistical data not shown); similar results were obtained by
comparison of changes from baseline in IL-7-treated versus
untreated animals (Figure S3 in Text S1). The statistical
differences between treated and untreated animals remained
significant when the analysis of total, naı ¨ve, memory and effector
CD4
+ T cells was restricted to CP animals, after exclusion of the 4
RP animals (Figure S2B in Text S1).
A detailed subset analysis of the memory CD4
+ T-cell
population was performed at selected time points. While in
untreated animals all memory CD4
+ T-cell subsets (CM,
transitional memory [TM] and effector memory [EM]) dramat-
ically declined during the acute phase of infection, none of these
subsets was quantitatively reduced in animals receiving IL-7
(Figure 3B). The protective effects of IL-7 on memory CD4
+ T
cells were not sustained after treatment interruption as shown by
the significant decline of all three subpopulations, compared to
baseline, on day 62 post-infection (Figure 3B).
Figure 2. Effect of IL-7 treatment on SIV replication. Mean levels
(6 SEM) of SIV plasma viremia (A) and p27Gag antigenemia (B) in
untreated (blue) and IL-7-treated (red) animals. No significant differ-
ences were observed between the two groups of animals, with the only
exception of SIV plasma viremia on day 4 post-infection, when IL-7-
treated animals showed higher levels compared to untreated controls
(indicated by the asterisk; p,0.05, by Wilcoxon rank sum test). The
grey-shaded area indicates the IL-7-treatment period. (C) Mean number
of genome equivalent copies (6 SEM) of SIV proviral DNA in
mononuclear cells from peripheral blood (days 14 and 77 post-
infection) and lymphoid tissues (GALT, days 14–16; axillary lymph
nodes, days 25–27 post-infection). No significant differences were
observed between the two groups of animals, p.0.05 by Wilcoxon rank
sum test.
doi:10.1371/journal.ppat.1002636.g002
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+ T
cells
IL-7-treated animals experienced sustained increases in all
subsets of circulating CD8
+ T cells throughout the acute phase of
infection, whereas a transient decline of naı ¨ve and memory CD8
+
T cells was observed in untreated animals (Figure 3A). When the
two groups of animals were compared, IL-7-treated monkeys
showed higher absolute numbers of peripheral CD8
+ T cells at
several time points (statistical data not shown); similar results were
obtained by comparison of changes from baseline between IL-7-
treated and untreated animals (Figure S3 in Text S1). Subset
analysis of memory CD8
+ T cells revealed no major changes in
untreated animals, whereas IL-7 induced significant increases in
all memory CD8
+ T-cell subsets (Figure 3B). However, on day 62
post-infection, CM CD8
+ T cells returned to baseline values, while
TM and EM CD8
+ T cells were significantly decreased in both IL-
7-treated and untreated animals (Figure 3A and 3B). The statistical
differences between treated and untreated animals remained
significant when the analysis of total, naı ¨ve, memory and effector
CD8
+ T cells was restricted to CP animals, after exclusion of the 4
RP animals (Figure S2B in Text S1).
Repeated IL-7 administrations induced only a transient
increase in T-cell proliferation but persistent signs of
apoptosis reduction
Longitudinal analysis of the levels of proliferation in freshly
isolated peripheral blood T cells revealed that IL-7 treatment
induced only a transient increase in the proportion of Ki67-
expressing CD4
+ T cells during the first week of treatment (day 25
and 23 prior to SIV infection), which returned to baseline levels at
the time of SIV inoculation (day 0); remarkably, there was no
further increase in proliferation after any of the subsequent IL-7
injections (Figure 4A). In contrast, CD8
+ T cells showed elevated
Ki67 expression both before SIV inoculation and at two time
points (day 4 and 11) after infection, even though the proportion of
cycling cells returned to baseline thereafter (Figure 4A).
Analysis of apoptosis in circulating T cells by Annexin-V
binding did not show significant elevations, compared to baseline,
Figure 3. Effect of IL-7-treatment on peripheral blood T-lymphocyte kinetics. (A) Mean absolute numbers (6 SEM) of circulating total,
naı ¨ve, memory and effector CD4
+ and CD8
+ T cells in untreated (blue) and IL-7-treated (red) animals. The naı ¨ve (CD28
+95
2), memory (CD28
+95
+) and
effector (CD28
295
+) T-cell subsets were identified using a combination of mAbs against CD28 and CD95. (B) Subset analysis of memory CD4
+ and
CD8
+ T cells in untreated (blue) and IL-7-treated (red) animals. The various memory T-cell subsets (central memory, CM; transitional memory, TM; and
effector memory, EM) were identified using a combination of CD28, CD95, CD62L and CD197/CCR7. Absolute counts for each T-lymphocyte
subpopulation were calculated by multiplying the percent values obtained by flow cytometry by the total lymphocyte counts obtained from the
complete blood counts (CBC). The grey shaded area indicates the IL-7-treatment period; blue and red asterisks denote significant differences versus
baseline values in untreated and IL-7-treated animals, respectively (* p,0.05, ** p,0.01, by paired Student’s t test).
doi:10.1371/journal.ppat.1002636.g003
IL-7 Protects CD4
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phase of SIV infection (Figure 4B), suggesting that the peripheral
blood compartment is largely spared from in vivo apoptosis during
primary infection; however, IL-7-treated animals exhibited
significant and sustained increases in the intracellular levels of
the anti-apoptotic protein Bcl-2 in both CD4
+ and CD8
+ T cells
during the first three weeks of treatment (Figure 4C). Represen-
tative histograms illustrating Ki67 expression, Annexin-V binding
and Bcl-2 expression in CD4
+ and CD8
+ T cells from one
untreated (#749) and one IL-7-treated (#746) animals are shown
in Figure S4 in Text S1. Altogether, these results suggested that
numerical expansion due to proliferation was not a major factor
contributing to the lack of decline of circulating CD4
+ T cells seen
in IL-7-treated animals while a decreased sensitivity to apoptosis
was likely involved. In contrast, both proliferation and apoptosis
reduction may have contributed to the sustained numerical
increases documented in circulating CD8
+ T cells.
Effects of IL-7 treatment in lymphoid tissues
Next, we studied the effects of IL-7 in peripheral lymphoid
tissues. Lymph node biopsies were collected from treated and
untreated macaques on days 25–27 post-infection. The relative
proportions of total, naı ¨ve, memory and effector CD4
+ and CD8
+
T cells in lymph nodes were not significantly different between IL-
7-treated and untreated macaques, and the level of Ki67
expression was very low (,1%) in both groups of animals (data
not shown). Analysis of T-cell apoptosis by Annexin-V binding
and intracellular Bcl-2 expression did not show significant
differences between the two groups of animals despite a trend
toward reduced Annexin-V binding in memory CD4
+ and CD8
+
T cells and effector CD8
+ T cells from IL-7-treated macaques
(Figure 5A, upper panel); however, these differences became
statistically significant when the analysis was restricted to CP
animals, after exclusion of the 4 RP animals (Figure 5B, upper
panel). In accordance with the Annexin-V data, lymph node CD4
+
T cells from IL-7-treated macaques showed higher levels of
intracellular Bcl-2 when RP animals were excluded from the
analysis (data not shown).
Terminal ileum biopsies were obtained from all animals on days
14–16 post-infection. The yield of CD3
+ T cells from these
biopsies was highly variable (range=1.2–15.0% of the total cell
populations), underscoring the inherent difficulties in obtaining
mucosal specimens with comparable representation of the GALT
via retrograde ileoscopy. Regardless of this limitation, no
significant differences were detected in the relative proportions
of total, naı ¨ve, memory and effector CD4
+ T cells, as well as in the
CD4/CD8 ratio in the intestinal tissues of IL-7-treated vs.
untreated macaques (data not shown); likewise, the proportion of
Annexin-V-positive CD4
+ T cells was similar in the two groups
(Figure 5A, lower panel). In contrast, the proportion of Annexin-
V-positive CD8
+ T cells was lower in IL-7-treated animals
(p=0.041), primarily due to a reduction of apoptosis among
memory CD8
+ T cells (p=0.048) (Figure 5A, lower panel),
associated with a lower proportion of apoptosis-prone naı ¨ve CD8
+
T cells (p=0.024) (data not shown). The difference in the
proportion of Annexin-V-positive CD8
+ T cells remained
significant when RP animals were excluded from the analysis
(Figure 5B, lower panel).
IL-7 treatment elicited earlier and stronger SIV-specific
CD4
+ and CD8
+ T-cell responses
SIV-specific T-cell responses were evaluated at multiple time
points during and after the IL-7 treatment period by measuring
the intracellular production of IFN-c, IL-2 and MIP-1b in CD4
+
and CD8
+ T cells stimulated with peptide pools derived from the
SIV Tat and Gag proteins. SIV-specific T-cell responses were
detected at multiple time points in all animals, while we were
unable to document the presence of SIV-neutralizing antibodies in
serum at any time during acute primary infection in both
untreated and IL-7-treated macaques (data not shown). The total
number of Tat-specific CD8
+ T cells at the first time point
analyzed (day 21 post-infection) was significantly higher in IL-7-
treated than in untreated animals (p=0.017), whereas the
difference in Tat-specific CD4
+ T-cell responses was close to but
did not reach statistical significance (p=0.051) (Figure 6). Overall,
IL-7-treated animals displayed higher numbers of Gag-responding
CD4
+ and CD8
+ T cells at several time points, but the differences
did not reach statistical significance (Figure 6).
Qualitative analysis of SIV-specific T-cell responses revealed
that initially most Tat-specific (Figure 7A) and Gag-specific (Figure
S5 in Text S1) CD4
+ and CD8
+ T cells were monofunctional in
both groups of animals, producing a single cytokine (single-
producer, SP). When SP cells were analyzed separately from
double- and triple-producer cells (DP and TP), the difference
between IL-7-treated and untreated animals on day 21 was
significant for both CD4
+ and CD8
+ Tat-specific T cells (p=0.030
and 0.017, respectively; Figure 7B). The quality of the T-cell
responses evolved over time, with both Tat-specific (Figure 7B)
and Gag-specific (Figure S5 in Text S1) T cells acquiring some
degree of polyfunctionality over time. This phenomenon was more
Figure 4. Effect of IL-7-treatment on cellular proliferation,
apoptosis and Bcl-2 expression in peripheral blood T cells. (A)
Mean levels (6 SEM) of cellular proliferation, as measured by expression
of the cell-cycling marker Ki67, in CD4
+ and CD8
+ T cells freshly isolated
from untreated (blue) and IL-7-treated (red) animals. (B) Mean levels (6
SEM) of spontaneous apoptosis, as measured by Annexin-V binding, in
circulating CD4
+ and CD8
+ T cells from untreated (blue) and IL-7-treated
(red) animals. (C) Average MFI levels (6 SEM) of Bcl-2 expression in
circulating CD4
+ and CD8
+ T cells from untreated (blue) and IL-7-treated
(red) animals. The grey shaded area indicates the IL-7-treatment period.
The asterisks denote significant differences between untreated and IL-
7-treated animals (* p,0.05, ** p,0.01, by Wilcoxon rank sum test).
doi:10.1371/journal.ppat.1002636.g004
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significant difference in the proportion of the various functional
subpopulations of Tat-specific CD8
+ T cells on day 62 post-
infection (Figure 7C).
Discussion
While the progressive refinement of multi-drug ART protocols
has led to extraordinary advances in the treatment of chronic
HIV-1 infection, there is still uncertainty as to whether a complete
reconstitution of the immunologic function can be achieved even
after years of sustained virologic suppression [35]. The often
incomplete immunologic reconstitution in patients treated with
ART, which is linked to an increased incidence of adverse clinical
events [36], has prompted consideration of adjuvant therapies,
including treatment with cytokines of the common-c-chain family,
such as IL-2, IL-7 and IL-15, which are known to induce T-cell
expansions. However, the ability of such treatments to regenerate
fully competent naı ¨ve and memory T-cell pools remains
questionable as multiple lines of evidence indicate that the initial
damage caused by HIV-1 during acute primary infection is
irreversible [1,2,10], marking a critical event in the pathogenesis of
HIV-1 disease and precluding the success of any restoration
attempts enacted during the chronic phase. These considerations
underscore the need to aim adjuvant treatment strategies toward
immunologic preservation rather than reconstitution and, there-
fore, to implement such strategies at the earliest possible time after
the diagnosis of HIV-1 infection. In this study, we used a macaque
model to demonstrate that treatment with IL-7, the principal T-
cell homeostatic cytokine, can prevent the dramatic decline of
circulating naı ¨ve and memory CD4
+ T cells that occurs during
acute primary SIV infection. Although in the clinical setting IL-7
would presumably be associated with ART, as it was done in
phase-1 studies in patients with chronic HIV-1 infection [29,30],
we deliberately avoided the use of virus-suppressive drugs in order
to allow for an unbiased evaluation of the effects of IL-7 on CD4
+
Figure 5. Frequency of CD4
+ and CD8
+ T-cell subsets and analysis of spontaneous apoptosis in terminal ileum and lymph node
biopsies from untreated and IL-7-treated macaques. Lymph node (upper panels) and gut (lower panels) biopsies were obtained from all
animals on days 25–27 and on days 14–16 post-infection, respectively. (A) Mean levels of spontaneous apoptosis, as measured by Annexin-V binding,
in total, naı ¨ve, memory and effector CD4
+ and CD8
+ T cells isolated from axillary lymph node and terminal ileum biopsies from untreated (blue) and
IL-7-treated (red) animals. The differences between untreated and IL-7-treated animals were analyzed by unpaired t-test (similar results were obtained
by Wilcoxon rank sum test). (B) Mean levels of spontaneous apoptosis, as measured by Annexin-V binding, on total, naı ¨ve, memory and effector CD4
+
and CD8
+ T cells freshly isolated from axillary lymph node and terminal ileum biopsies from untreated (blue) and IL-7-treated (red) animals, after the
exclusion of 4 rapid progressor (RP) animals. The differences between untreated and IL-7-treated animals were analyzed by unpaired t-test.
doi:10.1371/journal.ppat.1002636.g005
Figure 6. SIV-specific T-cell responses in untreated and IL-7-
treated macaques. Mean absolute numbers (6 SEM) of total CD4
+
and CD8
+ T cells responding to overlapping peptides derived from the
Tat and Gag proteins of SIV in untreated (blue) and IL-7-treated (red)
animals. The asterisk indicates a significant difference between total
responses in IL-7-treated vs. untreated macaques.
doi:10.1371/journal.ppat.1002636.g006
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pathogenesis during primary infection. In fact, ART by itself
would have prevented the loss of CD4
+ T cells, limiting the scope
of our study. The fact that in acutely-infected macaques treatment
with IL-7 was able to protect naı ¨ve and memory CD4
+ T cells
even in the absence of ART suggests that the combination of IL-7
with virus-suppressive drugs would be even more effective in
maintaining the integrity of the CD4
+ T-cell pool during one of
the most critical phases in the pathogenesis of HIV-1 disease.
To elucidate the mechanisms responsible for the CD4-
protective effects of IL-7, we examined the kinetics of CD4
+ T-
cell proliferation and apoptosis, as well as the induction of SIV-
specific cellular immune responses during the course of IL-7
treatment. Some levels of proliferation, albeit low, were docu-
mented following the first injection of IL-7, presumably leading to
the observed initial expansion of the memory CD4
+ T-cell subset.
However, in agreement with data of IL-7 treatment in chronically
SIV-infected macaques [28], no further proliferation was seen
after any subsequent IL-7 injection, suggesting that repeated
administrations of fully glycosylated IL-7 at weekly intervals may
in fact induce tachyphylaxis, at least concerning the proliferative
effects of the cytokine. Conversely and in agreement with our
previous ex vivo findings [22], several observations pointed to a
reduction of apoptosis as one of the mechanisms responsible for
CD4
+ T-cell preservation in our IL-7-treated macaques. First,
while the levels of apoptosis in peripheral blood T cells did not
change significantly during primary SIV infection in either treated
or untreated animals, preventing the evaluation of the anti-
apoptotic effects of IL-7 in this compartment, there was a
sustained increase in the expression of the anti-apoptotic protein
Bcl-2, a marker of increased resistance to apoptosis, in circulating
CD4
+ and CD8
+ T cells from IL-7-treated animals. Second,
analysis of secondary lymphoid tissues (lymph nodes and GALT)
demonstrated a reduction of apoptosis in selected CD4
+ and CD8
+
T-cell populations in IL-7-treated macaques, even though these
tissues were only sampled at a single time point during the acute
phase due to the inherent difficulties in obtaining multiple tissues
from the same animal within a short period of time. This limitation
reduced our chances to document the full spectrum of anti-
apoptotic effects of IL-7. Of note, analysis of the GALT at the time
of peak SIV replication demonstrated that IL-7 reduced the
proportion of Annexin-V-binding CD8
+ T cells, particularly of the
memory phenotype, but not CD4
+ T cells. An important caveat
that must be considered in this setting is the inconsistent quality of
Figure 7. Qualitative analysis of SIV-specific T-cell responses in untreated and IL-7-treated macaques. (A) Mean absolute numbers (6
SEM) of CD4
+ and CD8
+ T cells producing one cytokine (single-producer, SP), two cytokines (double-producer, DP) or all three cytokines (triple-
producer, TP) in response to SIV Tat peptide stimulation in untreated (shades of blue) and IL-7-treated (shades of red) animals. The asterisks indicate
significant differences between SP T cells in untreated vs. IL-7-treated animals, as analyzed by Wilcoxon rank sum test. (B) Mean absolute numbers of
SIV Tat-responding CD4
+ and CD8
+ T cells in untreated (U) and IL-7-treated (IL-7) animals. The bars indicate the mean numbers of total responding
cells; the colors indicate the mean numbers of IFN-c, IL-2, or MIP-1b SP cells (shades of blue), IFN-c/IL-2, IFN-c/MIP-1b or IL-2/MIP-1b DP cells (shades
of green), and IFN-c/IL-2/MIP-1b TP cells (purple). The numbers above each bar indicate the fraction of monkeys that gave a measurable response
over background to SIV Tat peptides at the corresponding time point. The grey shaded areas indicate the IL-7-treatment period. The asterisk indicates
a significant difference between total responses in IL-7-treated vs, untreated macaques. (C) Qualitative analysis of SIV Tat-specific CD8
+ T-cell
responses in IL-7-treated and untreated macaques on day 62 post-infection. The pie charts indicate the average contribution of the various functional
subpopulations of Tat-responding CD8
+ T cells (single-, double- and triple-producing, SP, DP, TP, respectively) to the total number of Tat-responding
cells in untreated and IL-7-treated animals at day 62 post-infection. The p value was calculated by permutation analysis using the Spice software.
doi:10.1371/journal.ppat.1002636.g007
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high probability of sampling error due to a markedly variable yield
of lymphoid cells. Regardless, the fact that we did not observe even
a trend toward reduced apoptosis among GALT CD4
+ T cells
may reflect the fact that IL-7 is inactive against the direct
cytopathic effect of the virus, which has been identified as the
principal mechanism responsible for CD4
+ T-cell depletion in the
gut during the acute phase of the infection, whereas the role of
apoptosis in this context remains controversial [1,2]. Although a
more extensive investigation is warranted to confirm this
hypothesis, our data suggest that IL-7 treatment prevented the
decline of circulating CD4
+ T cells during the acute phase of SIV
infection by inducing an initial expansion of these cells combined
with their subsequent preservation via sustained pro-survival
effects.
Since IL-7 seemed to effectively preserve the pool of CD4
+ T
cells, which are the main cellular targets for SIV, one could have
anticipated considerable increases in the levels of virus replication
in acutely infected macaques treated with IL-7. However, despite
the absence of concomitant ART, we did not observe dramatic
increases in the levels of SIV replication during both the treatment
phase and the follow up period, with the only exception of the
earliest time point analyzed (day 4 post-infection) in which the
levels of SIV plasma viremia were significantly higher in IL-7-
treated than in untreated macaques. A trend toward higher levels
of SIV plasma viremia was seen at certain time points, particularly
day 35 and day 41 post-infection, but it did not reach statistical
significance even after exclusion from the analysis of the 4 animals
with rapid disease progression. We cannot rule out that this lack of
statistical significance was due to the low number of animals
included in the study (n=6 per group), even though the p values
remained far below the threshold for significance. Nevertheless, it
is undisputable that, if an enhancing effect of IL-7 on SIV
replication did occur, this effect was far less dramatic than that
documented for a related common-c-chain cytokine, IL-15, in a
similar experimental setting [33]. Indeed, IL-15 treatment of
macaques during the acute phase of SIV infection was shown to
induce a ,3 log increase in viral load, most likely due to increased
CD4
+ T-cell proliferation and activation, and to accelerate the
disease progression [33]. Various hypotheses can be formulated to
explain these striking differences between the outcomes of IL-7
and IL-15 treatment. First, the lack of strong induction of CD4
+
T-cell proliferation by IL-7, unlike IL-15, which was detectable
only transiently and only after the first IL-7 injection; of note, this
transient proliferative effect of IL-7 could have been responsible
for the significant increase in SIV plasma viremia at the earliest
time point tested (day 4 post-infection). Second, the induction of
early and vigorous SIV Tat-specific CD4
+ and CD8
+ T-cell
responses in IL-7-treated animals, as compared to untreated
animals, associated with the proliferation, expansion and activa-
tion of all CD8
+ T-cell subpopulations. Since Tat is a regulatory
protein expressed during the early phase of the viral life cycle, Tat-
specific T-cell responses presumably were able to halt the infection
before completion of a full replicative cycle, thereby preventing the
spread of infectious virus to other target cells. Of note, a
pronounced numerical increase was detected in EM CD8
+ T
cells, a functionally competent subset that was recently associated
with effective vaccine-elicited protection in macaques [37]. Thus,
it is plausible that the increased availability of target CD4
+ T cells
in IL-7-treated animals was counterbalanced by the effectiveness
of virus-specific cell-mediated immune responses resulting in the
observed minimal increases in SIV replication levels. An
interesting correlate of our findings was provided by a recent
study in mice acutely infected with LCMV, in which early
treatment with IL-7 augmented the number and functionality of
specific antiviral effector T cells, thereby reducing organ pathology
and promoting viral clearance [38]. Conversely, it is also possible
that the earlier and stronger Tat-specific CD4
+ and CD8
+ T-cell
responses observed in IL-7-treated animals resulted from a more
robust antigenic stimulation due to the higher amount of virus
detected in these animals at day 4 post-infection; indeed, strong
CD8
+ T-cell responses were also detected in IL-15-treated
animals, although they were incapable of controlling viral
replication [33]. Thus, the different mechanisms of action of IL-
7 and IL-15 on CD4
+ T cells, with IL-15 inducing high levels of
activation and proliferation mainly in memory CD4
+ T cells, the
preferential target of the virus, and IL-7 stimulating the
proliferation and renewal of naı ¨ve T cells too, thereby contributing
to the preservation and replenishment of the peripheral T-cell
pool, may account for the divergent effects of treatment with these
two cytokines. Although a more extensive investigation is
warranted in the perspective of a potential clinical use of IL-7 in
acute HIV-1 infection, it is important to emphasize that in a
therapeutic regimen IL-7 would always be administered in
combination with ART, thereby minimizing its possible enhancing
effects on viral replication.
Our results may have implications for devising new treatment
strategies for acute HIV-1 infection, whose clinical management
remains a challenge. A critical hurdle is the inherent difficulty in
identifying and treating patients at the earliest possible stage in
order to reduce the massive HIV-1 replication that occurs before
the development of virus-specific adaptive immune responses and
its deleterious effects on the immune system. The extent of viral
replication during the acute phase of SIV infection in macaques
has indeed been identified as a critical determinant of the natural
history of the disease [39]. Although early ART treatment was
reported to be beneficial on the induction and maintenance of
HIV-specific cellular immune responses [39–41], additional
studies in patients [10,42] and macaques [43] have shown limited
effects of ART alone on T-cell preservation in the intestinal lamina
propria, underscoring the importance of devising effective
adjuvant therapies. Indeed, even if ART is promptly initiated
during primary infection, its effects may not be sufficient for fully
preventing the immunologic damage caused by HIV-1, particu-
larly in the gastrointestinal tract, due to dishomogeneous drug
biodistribution or inactivation by P-glycoproteins within the
intestinal mucosa. Moreover, complete suppression of viral
replication could take several weeks, and indirect mechanisms of
cell destruction, such as bystander apoptosis, may remain active
for some time after the virus has ceased to replicate. Our data
provide a scientific basis for the clinical evaluation of IL-7, in
combination with ART, for the treatment of acute primary HIV-1
infection.
Materials and Methods
Ethics statement
The animals were housed and fed according to regulations
established in the Guide for the Care and Use of Laboratory
Animals and the Animal Welfare Act. The animal experiments
performed in this study were approved by the NIH Animal Care
and Use Committee (ACUC).
Animals and study design
Twelve colony-bred juvenile Rhesus macaques, housed at
Bioqual Inc. (Rockville, MD), were divided in two groups,
according to HLA haplotype and baseline CD4
+ T-cell counts
(Table S2 in Text S1): untreated controls (group 1) and IL-7-
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the first week of IL-7 treatment, then twice weekly for the entire
treatment period and then once per week; terminal ileum biopsies
were obtained on day 14–16 post-infection; lymph node biopsies
were obtained on day 25–27 post-SIV infection. Since one animal
in the control group (H744) was lost on day 14 post-infection
during intestinal biopsy, all the data from day 14 onwards refer to
a total of 11 animals.
IL-7 treatment and SIV infection
Recombinant glycosylated simian IL-7 (Cytheris, France) was
employed inthis studysinceithasa considerably longerhalf-life and
greater stability (M. Morre et al., unpublished results) than the non-
glycosylated form that had been employed in several previous
studies [27,28]. IL-7 was administered subcutaneously to the 6
monkeysincludedingroup2ataconcentrationof50 mg/kgofbody
weight once per week for a total of 7 consecutive administrations.
To allow for the achievement of steady-state plasma levels of the
cytokine prior to SIV infection, treatment was initiated 1 week
before SIV inoculation (day 27). On day 0, all 12 monkeys were
inoculated intravenously with 100 macaque infectious doses of the
pathogenic strain SIVmac251, kindly provided by Dr. R. C.
Desrosiers. Multiple clinical, immunological and virological param-
eters were monitored throughout the acute phase of infection, as
well as for a follow-up period of 6 months post-infection.
Measurement of plasma IL-7 concentrations
The concentration of IL-7 in serial plasma samples was
measured using a high-sensitivity commercial ELISA (Quantikine
HS, R&D Systems, Minneapolis, MN).
Peripheral blood cell counts and flow cytometric analyses
Peripheral blood was collected under sterile conditions in
vacutainer tubes with EDTA as anticoagulant and complete blood
cell count with differential was performed by a commercial
laboratory (Antech Diagnostics, Rockville, MD). Plasma was
separated by spinning whole blood at 5006g for 20 min at 4uC
without brake and stored at 280uC. PBMC were isolated by
gradient centrifugation using Lymphocyte Separation Medium
(LSM; MP Biomedicals). Blood was diluted in Phosphate Buffered
Saline (PBS), stratified over LSM and centrifuged at 5006g for
25 min at 4uC without brake. The mononuclear cell ring was
collected, and the PBMC were washed twice with PBS, counted
and used for cytofluorimetric analyses. The following monoclonal
antibodies (mAbs) were used for surface staining: CD28-FITC
(clone CD28.2), CD4-PerCpCy5.5 (clone L200), CD95-APC or
-PE (clone DX2), CD8-PECy7 (clone SK1), CD3-APCCy7 (clone
SP34-2), all from BD Biosciences. The naı ¨ve (CD28
+CD95
2),
memory (CD28
+CD95
+) and effector (CD28
2CD95
+) T-cell
subsets were identified as previously described [43]. At selected
time points, a more detailed characterization of the memory T-cell
compartment was performed by using a combination of the
following mAbs: CD45RA-FITC (clone 5H9), CD28-PECy7,
CCR7-APC (clone 3D12), CD3-V450, CD4-APCH7 (all from BD
Biosciences), and CD8-eFLOUR 605NC (clone RPA-T8;
eBioScience). As illustrated in Figure S6 in Text S1, central
memory T cells (TCM) were defined as CD45RA
2 CCR7
+
CD28
+, transitional memory T cells (TTM) as CD45RA
2 CCR7
2
CD28
+, and effector memory T cells (TEM) as CD45RA
2 CCR7
2
CD28
2. Additional mAbs were used to measure the expression of
other cell-surface markers, including the IL-7 receptor-a/CD127-
PE (clone hIL-7R-M21), CCR5-PE (clone 3A9), CXCR4-PE
(clone 12G5) and the activation markers HLA-DR-PE (clone
L243/G46-6) and CD25-PE (clone M-A251) (all from BD
Biosciences). Stained cells were analyzed by flow cytometry using
a BD FACSCanto collecting a minimum of 100,000 events per
sample. Flow data were analyzed using the Flowjo software (Tree
Star) or FCS Express (DeNovo Software).
Apoptosis was assessed by measuring the levels of Annexin-V
binding, using Annexin V-APC conjugated (BD Biosciences), after
surface staining, as previously reported [22]. Bcl-2 expression
levels and cellular proliferation were assessed as follows: after
surface staining, the cells were fixed and permeabilized using BD
Cytofix/Cytoperm solution (BD Biosciences) and incubated with
mAbs anti-Bcl-2-PE (clone Bcl-2/100) and anti-Ki67-PE (clone
B56) (BD Biosciences). Annexin-V binding and Bcl-2 expression
(Mean Fluorescence Intensity, MFI) were evaluated on various
CD4
+ and CD8
+ T-cell subpopulation by multicolor flow
cytometry using a BD FACSCanto, collecting a minimum of
100,000 events per sample, and flow data were analyzed with the
Flowjo software (Tree Star) or FCS Express (DeNovo Software)
applying a progressive gating strategy. Naı ¨ve memory and effector
T-cell subsets were identified using a combination of anti-CD95
and anti-CD28 antibodies [44] on CD3
+CD4
+ and CD3
+CD8
+
gated cells, as described above for surface staining experiments.
Measurement of SIV plasma viremia, proviral DNA and
antigenemia
Plasma SIV RNA levels were measured using a quantitative
real-time RT-PCR assay. Viral RNA was purified from 280 mlo f
cell-free plasma using the QIAamp Viral RNA kit (Qiagen, USA),
and stored at 280uC. The number of SIV RNA genome
equivalents was determined using a single-tube real-time RT-
RCR assay based on the AgPath-ID One-Step RT-PCR Kit
(Applied Biosystems, USA), under the following reaction condi-
tions: 10 min at 45uC (RT), 10 min at 95uC and 40 cycles of
15 sec at 95uC and 45 sec at 60uC (PCR). Primers (300 nm) and
probe (200 nm) were specifically designed within the SIV gag gene
to amplify a fragment of 91 bp. Forward primer: 59-GCAGAG-
GAGGAAATTACCCAGT-39; reverse primer: 59-ATTTTACC-
CAGGCATTTAATGTTC-39 (used for the RT phase); TaqMan
MGB probe, FAM-labelled: 59-ACAAATAGGTGGTAAC-
TATG-39. The copy number was determined by interpolation
on a standard curve of a DNA plasmid carrying a fragment of the
SIV gag gene containing the RT-PCR amplicon (serial 10-fold
dilutions from 10
0 copies/reaction to 10
6 copies/reaction).
Forward cloning primer: 59-GCAGAGACACCTAGTGATG-
GAAAC-39; reverse cloning primer: 59-TCTCCCACACAATT-
TAACATCTG-39.
The SIV proviral DNA load was measured by real-time PCR
using the same primers and probe as in the plasma viremia assay.
Normalization for cell number was performed by quantification of
a non-polymorphic single-copy gene, CCR5. Additional details
about the method have been reported [45].
SIV p27Gag antigenemia was measured by using the SIV Core
Antigen Assay (Coulter Corporation, Miami, USA) according to
the manufacturer’s instructions. All samples were initially tested
undiluted and retested at 1:10 dilution if necessary. Plates were
read using an end-point protocol with a microplate spectropho-
tometer (Bio-Rad Instruments).
Measurement of anti-SIV antibodies
Anti-SIV monkey IgGs were quantified using a home-made
ELISA. Briefly, plates were coated overnight at 4uC with 1 mg/ml
of total SIV protein extract, obtained by lysing with 1% Triton x-
100 for 1 hour at room temperature the SIV isolate SIVmac251/
SupT1-CCR5 CL30 (from the AIDS & Cancer Virus Program,
NCI, NIH, Frederick). The following day the plates were washed
IL-7 Protects CD4
+ T Cells in Acute SIV Infection
PLoS Pathogens | www.plospathogens.org 9 April 2012 | Volume 8 | Issue 4 | e1002636and blocked for 1 hour. Samples were then added to each well,
initially undiluted and re-tested diluted 1:5 or 1:20, whenever
needed. Plates were then incubated with biotinylated goat anti-
human IgG (Sigma-Aldrich, #B1140) and HRP-conjugated
streptavidin (R&D Systems), and read at a wavelength of
450 nm with a reference set at 570 nm on a microplate
spectrophotometer (Bio-Rad Instruments). The presence of
neutralizing anti-SIV antibodies in the sera of infected untreated
and IL-7-treated animals was tested using an envelope-mediated
fusion assay with PM1 cells chronically infected with SIVmac251 as
effector cells and Hela (TZM-bl) cells expressing human CD4 and
CCR5 as target cells.
Terminal ileum and lymph node biopsies
Ileum biopsies were performed by retrograde ileoscopy on day
14–16 post-infection. At least 6–8 punch biopsies were obtained
from the terminal ileum of each animal, immediately placed in
cold RPMI medium and then processed within 3 hours of
excision. During the procedure, one animal (H744) suffered an
intestinal perforation and was lost. Ileum biopsies were digested in
Iscove’s media supplemented with 2 mg/ml Type II collagenase
(Sigma-Aldrich) and 1 U/ml DNase I (Sigma-Aldrich) for 30 min
at 37uC. After digestion, the samples were passed through a 70 mm
strainer, and the suspended cells were washed twice with RPMI
media supplemented with 10% heat-inactivated FBS.
Lymph node excisional biopsies were performed on day 25–27
post-infection on axillary lymph nodes from all animals. Lymph
nodes were cut longitudinally in two halves, one of which was
stored at 280uC. The remaining half was finely minced using
sterile scalpels and mechanically smashed to release lymphoid cells
into the media. Cells were then washed, passed through a 70 mm
strainer and stained for surface and intracellular markers as
described above.
Analysis of SIV-specific T-cell responses
SIV-specific CD4
+ and CD8
+ T-cell responses were analyzed by
measuring intracellular cytokine production after antigen stimu-
lation. Frozen samples of PBMC were thawed in RPMI 10% FBS
and rested at 37uC for at least 5 hrs. Cells were then plated at
5610
5 cells/well in a 96-well round-bottom plate in RPMI 10%
FBS in the presence of purified anti-CD28 and anti-CD49d mAbs
both at a final concentration of 1 ng/ml. Two pools of SIV-gag
peptides and one pool of SIV-tat peptides (from NIBSC, EVA
Centre for AIDS reagents) at a final concentration of 1 mg/ml
(each peptide) and Staphylococcus aureus Enterotoxin B (SEB, Sigma)
as positive control at a final concentration of 2 mg/ml were added
to the samples in a total volume of 200 ml. A negative control with
no stimulation was included. After 1 hr incubation at 37uC, 5%
CO2,1ml of Brefeldin A (BD GolgiPlug, BD Biosciences) was
added to each well, and the plates were incubated for an additional
11 hrs. At the end of the incubation period the cells were
transferred to 96-well V-bottom plates and washed twice with PBS
before surface intracellular staining. Cells were stained first with
LIVE/DEAD Fixable Dead Cell Stain reagent (Invitrogen by Life
Technologies) at a concentration of 1 ml/10
6 cells for 20 min at
4uC and then with the mAbs to lineage antigens (CD3-V450 and
CD4-APCH7, BD Biosciences), before fixation and permeabiliza-
tion with BD Cytofix/Cytoperm Buffer (BD Biosciences). After
washing with BD PermWash Buffer (BD Biosciences), the cells
were incubated for 20 min at 4uC with anti-MIP-1b-PE (clone
D21-1351), anti-IFN-c-PECy7 (clone P2G10) and anti-IL-2-APC
(clone MQ1-17H12; all from BD Biosciences), washed again and
analyzed on a BD FACSCanto instrument. T-cell responses were
analyzed using Flowjo (Tree Star) and Spice softwares.
Statistical analysis
Statistical analysis was conducted using the softwares SAS
(version 9.1 for Windows), S-Plus (version 6.2 for Windows),
StatView (version 5.0.1 for Macintosh) and GraphPad Prism
(version 4.0b for Macintosh). Paired Student’s t-tests were used for
the comparison between different time points within the same
animal group (untreated or IL-7-treated). Non-parametric Wil-
coxon rank sum tests were used to analyze differences between IL-
7-treated and untreated animals. To compare untreated and IL-7-
treated animals with respect to changes from baseline to multiple
time points simultaneously the O’Brien test was used (for a more
detailed description see Supporting Information online).
Supporting Information
Text S1 Text S1 contains Supplementary Methods (study design;
statistical analysis), Supplementary Data (features of animals with
rapid disease progression; T-cell dynamics), Table S1 (p values for
SIV viremia and antigenemia), Table S2 (MHC haplotype and
baselineT-cellcounts in study groups),Figure S1 (SIV replication in
conventional vs. rapid progressors), Figure S2 (data reanalysis after
exclusion of rapid progressors), Figure S3 (T-cell changes from
baseline), Figure S4 (representative Ki67, Annexin-V and Bcl-2
profiles), Figure S5 (SIV Gag-specific T-cell responses), Figure S6
(gating strategyfornaı ¨veand memoryT cells).Text S1alsocontains
references and explanatory legends to Tables and Figures.
(PDF)
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